Silexion Therapeutics prices $2.5m offering to fund SIL204 trial

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A modern, bright medical imaging room contains a white CT scanner with an adjustable patient table, illuminated by natural light from windows, and a wall-mounted computer workstation on the right.

Silexion Therapeutics has priced a public offering of approximately 3.85 million ordinary shares and accompanying Series E warrants at $0.65 per unit, expecting gross proceeds of around $2.5 million. The offering is expected to close on or about 13 August 2026, subject to customary conditions, with H.C. Wainwright acting as exclusive placement agent.

The Cayman Islands-incorporated, NASDAQ-listed company said it intends to direct net proceeds toward advancing the clinical programme for SIL204, its lead second-generation candidate, and for general corporate purposes.

The SIL204 programme

SIL204 is a small interfering RNA (siRNA) designed to suppress mutant KRAS, a protein long regarded as one of the most intractable targets in oncology. A Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer has been initiated at Tel Aviv Sourasky Medical Center. Silexion said its earlier first-generation candidate demonstrated a positive trend against a chemotherapy control in a Phase 2a study, which the company cites as supporting rationale for the current programme.

The company is pursuing an RNAi approach rather than the small-molecule KRAS inhibitor strategy that has attracted significant investment and regulatory attention elsewhere. Sotorasib and adagrasib, the two approved KRAS G12C inhibitors, target only one specific KRAS mutation; the broader universe of KRAS-mutant cancers, including the G12D variant predominant in pancreatic cancer, remains largely without approved targeted options, which is the clinical gap Silexion is attempting to address.

Market context and competitive positioning

The KRAS-targeting space has grown considerably more competitive since the approval of the first small-molecule KRAS inhibitors. Several companies are developing mutation-agnostic or RNAi-based approaches to suppress KRAS more broadly, and pancreatic cancer has attracted considerable research interest given its poor prognosis and limited treatment options. Silexion's siRNA strategy is differentiated from small-molecule approaches, but RNA-based therapeutics face their own delivery challenges, particularly for solid tumours, and the field is watching closely for durable clinical responses.

At $2.5 million, this is a small raise by industry standards. It signals that Silexion is operating with tight capital discipline and that existing institutional appetite for the story at current share prices is limited. The combined offering price of $0.65 per share, with warrants exercisable immediately at the same price, reflects the company's micro-cap status and the financing pressures common among early-stage NASDAQ biotechs in the current market environment. The forward-looking disclosures in the company's SEC filings explicitly flag risks around Nasdaq listing maintenance, which is a metric investors in this segment will monitor closely alongside clinical progress.

The next meaningful catalyst for Silexion will be clinical data readouts from the SIL204 Phase 2/3 study, though no timeline for interim or topline results was provided in the offering announcement.

Sector

Topic

Geography